Evidence map›Paper›PMID 30944609›Full record

ArticleOncology letters2019

Comparative analysis of CEACAM1 expression in thin melanomas with and without regression.

Luciana Nichita, Sabina Zurac, Alexandra Bastian, Patricia Stinga, Roxana Nedelcu, Alice Brinzea, Gabriela Turcu, Daniela Ion, Lucia Jilaveanu, Liana Sticlaru and 2 more

Open access · diamondAbstract read
In one paragraph

Article in Oncology letters, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.9field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 2 countries.

Luciana NichitaDepartment of Pathology, Faculty of Dentistry, Carol Davila University of Medicine and Pharmacy, 010221 Bucharest, Romania.
Sabina ZuracDepartment of Pathology, Faculty of Dentistry, Carol Davila University of Medicine and Pharmacy, 010221 Bucharest, Romania.
Alexandra BastianDepartment of Pathology, Faculty of Dentistry, Carol Davila University of Medicine and Pharmacy, 010221 Bucharest, Romania.
Patricia StingaDepartment of Pathology, Colentina University Hospital, 020125 Bucharest, Romania.
Roxana NedelcuDepartment of Physiopathology, Faculty of Medicine, Carol Davila University of Medicine and Pharmacy, 020021 Bucharest, Romania.
Alice BrinzeaDepartment of Physiopathology, Faculty of Medicine, Carol Davila University of Medicine and Pharmacy, 020021 Bucharest, Romania.
Gabriela TurcuDepartment of Physiopathology, Faculty of Medicine, Carol Davila University of Medicine and Pharmacy, 020021 Bucharest, Romania.
Daniela IonDepartment of Physiopathology, Faculty of Medicine, Carol Davila University of Medicine and Pharmacy, 020021 Bucharest, Romania.
Lucia JilaveanuDepartment of Medicine, Section of Medical Oncology, Yale University School of Medicine, New Haven, CT 208028, USA.
Liana SticlaruDepartment of Pathology, Colentina University Hospital, 020125 Bucharest, Romania.
Cristiana PoppDepartment of Pathology, Colentina University Hospital, 020125 Bucharest, Romania.
Mirela CiopleaDepartment of Pathology, Colentina University Hospital, 020125 Bucharest, Romania.
Carol Davila University of Medicine and Pharmacy · ROSpitalul Clinic Colentina · ROYale University · US

Funding

Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
Inherent tropism and/or immune modulation in melanoma brain metastasisR01CA204002 · NCI · YALE UNIVERSITY · PI JILAVEANU, LUCIA BEATRICE · 2017 to 2021
$1.9M
NCATS NIH HHS UL1 TR001863NCI NIH HHS R01 CA204002
6 · The paper itself

Abstract

Carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1) is a key molecule in several intracellular and intercellular signaling pathways, with multiple functional and structural roles. CEACAM1 expression in melanoma is often described in the invading part of the tumor and has been associated with increased melanoma cells invasion and migration. We studied CEACAM1 expression in regressing versus non-regressing thin melanomas, knowing that phenomenon of regression represents a valuable model for understanding tumor immunity. In melanoma, through homophilic interactions, CEACAM1 inhibits natural killer cell activity, inhibits effector functions of tumor infiltrating lymphocytes, such as cytotoxicity and interferon-γ release. We present a retrospective study including 53 consecutive cases of thin melanoma, 21 with regression and 32 without regression. Comparative analysis of CEACAM1 expression in regressed and non-regressed areas from melanomas with regression and in non-regressed melanomas was performed. We used three different clones of CEACAM1: AA 1-428, extracellular domain, rabbit; AA 1-428, mouse, clone 8B6E2F4; and AA 1-468, full length, mouse, clone 2F6. All three clones had similar reactivity. We identified membrane positivity of tumor cells in non-regressed melanomas and in non-regressed areas in melanomas with regression. Remaining tumor cells in regressed areas were mostly negative for CEACAM1. In non-regressed lesions, there was a stronger positivity of CEACAM1 in the deep invasive front. In thin melanomas, CEACAM1 overexpression is related with invasiveness, suggesting that CEACAM1-positive melanomas are more aggressive. Also, in areas of regression tumor cells lose CEACAM1 expression, probably correlated with the presence of natural killer cells.

Indexed as

CEACAM1invasion frontmelanomaregression

Identifiers

PMID30944609
PMCPMC6444332
OpenAlexW2917960768

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.